Efficacy and Safety of Bortezomib Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in Japanese Patients (Pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL) Not Considered for Transplantation Enrolled in the International, Randomized, Phase 3 LYM-3002 Study (NCT00722137)

被引：0

作者：

Ogura, Michinori ^{[1
]}

Pei, Lixia ^{[2
]}

Rooney, Brendan ^{[3
]}

van de Velde, Helgi ^{[4
]}

Cavalli, Franco ^{[5
]}

机构：

[1] Suzuka Natl Hosp, Natl Hosp Org, Suzuka, Japan

[2] Janssen Res & Dev LLC, Raritan, NJ USA

[3] Janssen Res & Dev, High Wycombe, Bucks, England

[4] Janssen Res & Dev, Beerse, Belgium

[5] Osped San Giovanni Bellinzona, Oncol Inst Southern Switzerland, Bellinzona, Switzerland

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4